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STUDY
Reliability of the Roenigk Classification of Liver
Damage After Methotrexate Treatment for Psoriasis
A Clinicopathologic Study of 160 Liver Biopsy Specimens
Maartje A. M. Berends, MD; Martijn G. H. van Oijen, MSc; Josje Snoek, MSc; Peter C. M. van de Kerkhof, MD, PhD;
Joost P. H. Drenth, MD, PhD; J. Han van Krieken, MD, PhD; Elke M. G. J. de Jong, MD, PhD
Objective: To determine the interobserver reliability
of the Roenigk score as a classification system of liver
damage and its possible consequences for clinical
practice.
Design: Retrospective study.
Setting: Academic research.
Patients:Onehundred sixty liver biopsy specimens from
patients with psoriasis receiving methotrexate treat-
ment were rereviewed and analyzed blindly by an expe-
rienced pathologist with an interest in liver pathologic
conditions.
Main OutcomeMeasure: Interobserver variation was
evaluated using  statistics.
Results: A high concordance was present in the evalu-
ation of the Roenigk grade of fibrosis (weighted =0.73;
95% confidence interval, 0.63-0.83). Agreementwas good
regarding the number of biopsy specimens for patients
whose clinical management should be changed (=0.71;
95% confidence interval, 0.56-0.87).
Conclusion: The Roenigk classification in the assess-
ment of liver fibrosis is a reliable scoring system.
Arch Dermatol. 2007;143(12):1515-1519
H EPATIC FIBROSIS AND CIR-rhosis represent a conse-quence of methotrexatetreatment in patientswithpsoriasis.1-6 Therefore, the
assessment of liver damage is essential in
the clinical management of these pa-
tients. Sequential liver biopsies followed
by Roenigk grading by a pathologist are
themainstay in the assessment of the stage
and degree of liver damage.7-9 Unfortu-
nately, liver biopsies may be associated
with sampling error, potential complica-
tions, and interobserver variability.1,7,9-13
Methotrexate-associated liver damage
in patients with psoriasis is graded accord-
ing to the Roenigk classification.1 The re-
sults of the Roenigk scoring system should
be reproducible, with little interobserver
error.
The Roenigk classification was devel-
oped by the Psoriasis Task Force (led by
dermatologists), is based on clinical ob-
servations, and has been recommended in
the American Academy of Dermatology
guidelines for monitoring methotrexate-
induced liver injury.1,9,14 However, the
Roenigk grading system is subjective, in-
cluding some features (such as nuclear
pleomorphism) of unclear significance,
and is insensitive to small changes, par-
ticularly when assessing fibrosis.1,15,16 Al-
though scoring seems to consider changes
such as steatosis and inflammation, their
presence or absence has no weight in the
allocation to more advanced grades. The
system categorizes all biopsy specimens
with more than minimal fibrosis as ad-
vanced fibrosis (Roenigk grade 3b) and
overestimates the degree of histologic
change. Accurate assessment is essential
because misclassification of pathologic
changes affects clinical management. For
example, if the degree of fibrosis is up-
graded from none (Roenigk grade 2) to
mild (Roenigk grade 3a), guidelines call
for a second liver biopsy within 6months
instead of a 1.5-g cumulative dose of
methotrexate.9 In the case of Roenigk grade
3b or 4, the guidelines recommend dis-
continuation of therapy.
In some European countries, the num-
ber of liver biopsies has declined for sev-
eral reasons. The use of the aminotermi-
nal propeptide of type III procollagen
(PIIINP) has reduced the number of liver
biopsies in Scandinavia and in Great Brit-
ain. Until recently, no noninvasivemethod
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has been available that could completely replace the liver
biopsy. In the case of a persistently elevated PIIINP, liver
biopsy is still advised.11,13,17 Given the critical nature of
this tool, we evaluated interobserver variation using a
sample of 160 liver biopsy specimens frommethotrexate-
treated patients with psoriasis.
METHODS
PATIENTS
We evaluated interobserver variation between several differ-
ent pathologists with an interest in liver pathologic routine clini-
cal practice and 1 of us (J.H.v.K.) in the assessment of the his-
topathologic degree of liver damage according to the Roenigk
scale in patients with psoriasis receiving methotrexate treat-
ment. All pathologists were trained at the same department of
pathology at the same hospital.
One hundred twenty-five patients with psoriasis had un-
dergone 278 liver biopsies while receiving methotrexate treat-
ment from November 1, 1976, to December 31, 2005. We ex-
cluded biopsies performed before December 31, 1995, because
these specimens were unavailable for review. In addition, 9 bi-
opsy specimens were excluded from analysis (6 because they
were unavailable from the department’s archives, 1was too small
to evaluate the degree of fibrosis, and 2 because the vanGieson–
stained slide was unavailable). One hundred sixty liver biopsy
specimens from 95 patients were reexamined independently
by 1 of us (J.H.v.K.) who was blinded to the clinical details of
the patients. Liver biopsy specimens were graded according to
the Roenigk classification (Table 1).1
HISTOLOGIC EXAMINATION
Percutaneous liver biopsy was performed via a right intercos-
tal approach using local lidocaine hydrochloride anesthesia. The
biopsy specimen was immersed in 2% formaldehyde and was
subsequently fixed with paraffin. Hematoxylin-eosin–stained
sections of liver tissuewere examined for steatosis, nuclear vari-
ability, hepatocyte necrosis, and lobular and portal tract in-
flammation. A van Gieson stain for collagen was used to as-
sess for the expansion of the portal tracts and for the presence
of pericellular and perivenular fibrosis.
PATHOLOGIC EXAMINATION
All liver biopsy specimens, sampled as part of the monitoring
process of methotrexate-induced hepatic injury, were graded
according to the Roenigk classification. A description of the
Roenigk classification is given in Table 1. Roenigk grade 1 in-
dicates normal tissue with no fibrosis, no or mild portal in-
flammation, and no or mild fatty changes and nuclear pleo-
morphism.Grade 2 indicates no fibrosis andmoderate or severe
fatty changes, nuclear pleomorphism, and portal inflamma-
tion. Grade 3a indicates mild fibrosis, portal fibrotic septa, ex-
tension into the lobuli, and portal tract enlargement. Grade 3b
indicates moderate or severe fibrosis. Grade 4 indicates cirrho-
sis, regenerating noduli, and bridging of the portal tracts.
STATISTICAL ANALYSIS
To judge the degree of interobserver agreement, we calculated
weighted  statistics for the 5-point Roenigk scale. For analy-
sis of clinical consequences, we dichotomized the Roenigk score
into “no changes of treatment necessary” (Roenigk grades 1 and
2) and “change of treatment necessary” (Roenigk grades 3a, 3b,
and 4) for all observations. For agreement of the dichoto-
mized data, we again used  statistics. Interpretation of the 
statistics was performed using the scale described by Landis and
Koch,18 in which  statistics less than 0.4 indicate poor agree-
ment,  statistics between 0.4 and 0.6 indicate moderate agree-
ment, between 0.6 and 0.8 good agreement, and greater than
0.8 indicate excellent agreement.19
To visualize agreement, we plotted a Bland-Altman curve
for the 5-point Roenigk score. Using a 2-sided t test, we tested
whether the overall mean differences differed statistically sig-
nificantly from 0. All analyses were undertaken using statisti-
cal software (SAS version 8.2; SAS Institute Inc, Cary, North
Carolina).
RESULTS
DEMOGRAPHICS
Ninety-five patientswith psoriasis (44 female and51male)
underwent a liver biopsy between December 31, 1995,
andDecember 31, 2005. Themaximumprescribedweekly
dosage of methotrexate was 12.5 mg (range, 7.5-25mg).
Patients received amedian cumulativemethotrexate dose
of 2051mg (range, 119-20 235mg) during amedian fol-
low-up period of 202 weeks (range, 20-1763 weeks).
LIVER BIOPSY SPECIMENS
The concordance between the Roenigk grades as scored
during routine assessment and at subsequent scoring by
the second pathologist was high (weighted =0.73;
95% confidence interval, 0.63-0.83). The agreement
was higher for biopsy specimens that were graded as
Roenigk grade 1, which was the most common Roenigk
score (Figure). The mean difference was 0.03 and did
not significantly differ from 0 (P .05). Among liver bi-
opsy specimens that resulted in a change of clinical
management (Roenigk grades 3a, 3b, and 4), we like-
Table 1. Roenigk Classification System
Fatty Change Nuclear Pleomorphism Fibrosis Necroinflammation Roenigk Gradea
Mild or none Mild or none None With or without mild portal inflammation 1
Moderate or severe Moderate or severe None Moderate or severe portal inflammation 2
With or without With or without Mild (fibrosis extending into acini) With or without 3a
With or without With or without Moderate or severe With or without 3b
With or without With or without Cirrhosis With or without 4
aSee the “Pathologic Examination” subsection of the “Methods” section for an explanation of Roenigk grades.
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wise observed a good correlation (=0.71; 95% confi-
dence interval, 0.56-0.87).
The initial routine examination had graded 113 liver
biopsy specimens as Roenigk grade 1, 21 as grade 2, 22
as grade 3a, 3 as grade 3b, and 1 as grade 4 (Table 2).
After reexamination of all liver biopsy specimens by the
second pathologist, 118 were graded as grade 1, 18 as
grade 2, 18 as grade 3a, 4 as grade 3b, and 2 as grade 4.
Six liver biopsy specimens originally scored as Roenigk
grade 1 were scored differently by the second patholo-
gist (3 as grade 2 and 3 as grade 3a). Ten liver biopsy
specimens originally scored as grade 2 were subse-
quently scored differently (2 were upgraded to grade 3a,
while 8 were downgraded to grade 1). Nine liver biopsy
specimens originally scored as grade 3a were scored dif-
ferently by the second pathologist (2 as grade 3b, 4 as
grade 2, and 3 as grade 1). Finally, 1 liver biopsy speci-
men originally scored as grade 3b was subsequently up-
staged to grade 4.
CLINICAL CONSEQUENCES
OF DIFFERENCES IN SCORING
Fourteen biopsy specimens were downgraded or up-
graded to such an extent that it would have affected clini-
cal management (Table 3). Seven biopsy specimens
graded as Roenigk grade 3a were downgraded by the sec-
ond pathologist to grade 2 or 1. Because of the original
grade, follow-up biopsies in 3 patients were performed
after 5 to 10 months, and methotrexate treatment in
1 patient was discontinued after 5 months. Three bi-
opsy specimens were upgraded by the second patholo-
gist from grade 1 to 3a, 2 biopsy specimens from grade 2
to 3a, and 2 biopsy specimens from grade 3a to 3b. In
the latter 2 cases, this assessment resulted in follow-up
biopsies after 9 and 14 months that demonstrated his-
tologic findings corresponding to grade 3a. One of these
patients is still being treated with methotrexate. In the
other patient,methotrexate treatmentwas continued, and
2 more biopsies were performed. Both biopsy speci-
mens demonstrated histologic findings corresponding to
grade 3a. Methotrexate treatment was discontinued for
an unknown reason.
COMMENT
Our objectives were to determine the interobserver re-
liability of the Roenigk score as a classification system
of methotrexate-induced liver damage and to assess the
consequences for clinical practice. The results of this study
show that the Roenigk classification is a reliable scoring
system for the assessment of liver fibrosis.
The study revealed high concordance between the first
and second observations. Also, there was good agree-
ment onbiopsy specimens that resulted in aRoenigk grade
that necessitated change of clinical management (bi-
opsy specimenswith grades 3a, 3b, and 4). Although only
a small percentage of the biopsy specimens was scored
differently by the second pathologist, it would have re-
sulted in a clear change in the clinical decisions made.
Grade 3a requires more frequently performed liver bi-
opsies (within 6 months instead of a 1.5-g cumulative
dose of methotrexate), and grades 3b and 4 necessitate
interruption and cessation of methotrexate treatment.9
Periodic liver biopsies are recommended by interna-
tional guidelines4,9,14 on methotrexate treatment in pa-
tients with psoriasis, and the Roenigk score has been rec-
ommended in the American Academy of Dermatology
guidelines4,9,14 to classifymethotrexate-induced liver dam-
age. However, the Roenigk scale has not been validated
or used (to our knowledge) in the evaluation of any other
liver disease.1 Furthermore, the Roenigk scale is subjec-
tive and is insensitive to small changes, particularly when
assessing fibrosis.1,16 Scoring systems for liver damage such
as theMetavir, Scheuer, and Ishak classifications are well
established for hepatitis C and for some forms of nonvi-
ral hepatitis; these scoring systems are more sensitive to
small changes, and studies1,20-24 demonstrated good agree-
ment for fibrosis assessment. As far as we know, there
are no studies evaluating the validity and interobserver
reliability of the Roenigk score. However, 2 studies com-
pare the Roenigk classification with other scoring sys-
tems. One study15 compares the Roenigk score with a
Table 2. Numbers of Slides Assigned to the Roenigk Grades
by the Pathologistsa
Roenigk Grade First Pathologist Second Pathologist
1 113 118
2 21 18
3a 22 18
3b 3 4
4 1 2
aSee the “Pathologic Examination” subsection of the “Methods” section
for an explanation of Roenigk grades.
2
–2
–1
1
0
1 43b3a2
Mean Score
Di
ffe
re
nc
e 
Sc
or
e
Figure. Bland-Altman curve. The graph shows the absolute difference
between the initial and subsequent scores (on the y-axis) against the mean
of both scores (on the x-axis) for each observation. In the graph, the size of
the crosses indicates how often a pair of observations is found. The red line
indicates the 0.03 overall mean difference between the initial and subsequent
scores.
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semiquantitative histologic scoring system for the evalu-
ation of hepatic fibrosis in patients with rheumatoid ar-
thritis treated with methotrexate. A statistically signifi-
cant correlation was found between the 2 classification
systems, but the semiquantitative histologic scoring sys-
temwasmuchmore sensitive than the Roenigk score for
the assessment of hepatic fibrosis. Another study1 com-
pared 3 scoring systems for the evaluation of hepatic fi-
brosis in patients with psoriasis treated with methotrex-
ate. The Roenigk classification was compared with the
Scheuer and Ishak scoring systems and seemed to cor-
relate poorly with both systems.
The already described simplification of the Roenigk
classification may have improved the interobserver reli-
ability in our study. This raises the question of whether
the Roenigk classification is the best-designed scoring sys-
tem to classify methotrexate-induced liver injury. How-
ever, that was not the objective of our study. The Roenigk
classification is used by many pathologists to classify
methotrexate-induced liver fibrosis. In this study, it is
shown that the interobserver reliability is good.
In 8% of the liver biopsy specimens, a different clini-
cal decision would have been made based on disagree-
ment between the first and second observers. When this
leads to more frequently performed liver biopsies, seri-
ous consequences arise for the patient. Patients will be
at greater risk formorbidity andmortality associatedwith
liver biopsies such as postprocedural pain, bleeding, and
(less often) pneumothorax. Also, an increase in liver bi-
opsies has socioeconomic consequences such as ab-
sence from work. Unnecessary liver biopsies should be
avoided, and there is a need for alternative noninvasive
and reliable methods to monitor methotrexate-induced
liver injury in patients with psoriasis. Several noninva-
sive methods have been tested as a screening for liver fi-
brosis and liver cirrhosis (eg, the Fibrotest, Fibroscan,
and PIIINP).11,13,17,25 Another serious consequence would
be the risk of missed pathologic findings that would ne-
cessitate discontinuing methotrexate treatment or un-
dergoing another liver biopsy in 6 months.
This study was composed of a rereview of 160 liver
biopsy specimens by 1 of us (J.H.v.K.). However, the ret-
rospective nature of the study has some limitations, which
might be reflected in the differences in the results found.
Slides could have lost some of their stains, and observa-
tion of slides serially (by the second pathologist) or in-
dividually (by the first pathologist) could have resulted
in some of the differences.
One biopsy specimen was excluded from the study be-
cause it was too small to evaluate the degree of fibrosis. A
hepatologist experienced in performing liver biopsies and
in repeating liver biopsy procedures is essential for obtain-
ing adequate specimens and for the safety of the patient.
Based on this study, we conclude that the interob-
server reliability of the Roenigk classification is good and
that it can be used as a scoring system for methotrexate-
induced liver damage. However, the clinical conse-
quences of rereviewwere substantial. Experiencedpatholo-
gists with an interest in liver pathologic conditions are
recommended, aswell asparticular attention tobiopsy speci-
mens with Roenigk grades 3a and 3b. The search for non-
invasive alternatives to liver biopsy should be continued.
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